Tapan M. Kadia

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-9892-9832

发表论文 1855 篇 · 总被引 34306 次 · h-index 91

代表论文

• Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia (2026 · Cancer)
• Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model (2026 · Journal of Clinical Oncology)
• Table S20 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial (2026)
• Figure S7 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial (2026)
• Table S5 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial (2026)
• Figure S6 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial (2026)